EyePoint opened lower at $0.35, compared with its previous close of $0.36. In the last trading session, the stock traded between $0.31 and $0.36. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in EyePoint is now worth
$ 2.30
Resulting in a loss of
$ 97.70 (97.70%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 13 Analysts
Buy
15.38%
Hold
76.92%
Sell
7.69%
Markets Today
Today's Change
$-0.04 (-11.10%)
Day High
$0.36
Day Low
$0.31
Day Open
$0.35
Prev Close
$0.36
Volume
57,43,470
1W Return
-18.93%
1M Return
-90.44%
3M Return
-97.57%
6M Return
-97.73%
1Y Return
-97.28%
Fundamentals
Market Cap ($ Mn)
27
PE Ratio
-
PB Ratio
2.29
PEG Ratio
-
ROE
-83.61%
ROCE
-80.78%
EPS (TTM)
$-1.11
Investment Returns
1 Week
-18.93%
1 Month
-90.44%
3 Months
-97.57%
6 Months
-97.73%
9 Months
-97.53%
Financials
Quarterly
All values in $ Mn
11.6
Dec 24
24.5
Mar 25
5.3
Jun 25
1.0
Sep 25
0.6
Dec 25
0.5
Jun 26
Updates
4Nov
Pomerantz investigates EyePoint claims following clinical trial failures
Pomerantz LLP investigates EyePoint for potential securities fraud following two Phase 3 trial failures. Stock price fell 66.98% in August and 85.28% in October after DURAVYU missed primary endpoints. Company terminated wet AMD program and cut 53% of workforce after LUCIA trial failure. Cumulative stock decline exceeds 90% since the first negative clinical data release.
9 days ago
21Oct
Laidlaw & Co. downgrades EyePoint to Hold
Laidlaw & Co. analyst Yale Jen downgrades EyePoint from Buy to Hold. The rating change reflects a revised investment stance on the company.
23 days ago
20Oct
RBC Capital cuts EyePoint price target to $1, maintains Sector Perform
RBC Capital lowered EyePoint's price target from $5 to $1. Analyst Lisa Walter maintained a Sector Perform rating. The price target reduction represents an 80% cut. Rating remains unchanged despite significant valuation adjustment.
23 days ago
20Oct
HC Wainwright reiterates Neutral rating on EyePoint
HC Wainwright & Co. reiterated Neutral rating on EyePoint. Analyst Yi Chen maintained the existing stance. No change in rating or price target disclosed.
23 days ago
19Oct
EyePoint cuts 53% workforce and halts wet AMD trials after Phase 3 miss
Workforce reduced by 53% to cut costs by $30 million annually. Wet AMD Phase 3 trial failed primary endpoint; trials halted early. Stock price fell 85.46% to $0.43, hitting a 52-week low. Focus shifts entirely to diabetic macular edema (DME) program. Cash position stands at $118 million as of September 30, 2026.
24 days ago
23Sep
Pomerantz investigates EyePoint after stock falls 67% on trial miss
Pomerantz LLP is investigating EyePoint, Inc. for potential securities fraud. EyePoint's stock fell 66.98% to $4.87 per share on August 17, 2026. The decline followed the failure of the DURAVYU Phase 3 LUGANO trial to meet primary endpoints. Investors are advised to contact Pomerantz LLP regarding class action participation.
